

## **Inhibition of interleukin 17 production by curcumin in mice with collagen-induced arthritis**

**Yoshihiro Okamoto, Mayuri Tanaka, Takashi Fukui, Toshiyuki Masuzawa**

Laboratory of Immunology and Microbiology, Faculty of Pharmacy, Chiba Institute of Science, 3 Shiomi-cho, Choshi, Chiba 288-0025, Japan

### **Abstract**

**Autoimmune inflammatory diseases, such as rheumatoid arthritis (RA), have been thought to be mediated by the cytokine interleukin 17 (IL-17). Curcumin (1,7-Bis (4-hydroxy-3-methoxyphenyl)-1,6 heptadiene- 3, 5-di-one) is an active ingredient derived from rhizomes of *Curcuma longa* Linn., displaying remarkable anti-inflammatory. Curcumin has been reported to have the suppressive effect on the development of an experimental animal model of RA, collagen-induced arthritis (CIA). However, there is no evidence for the effect of curcumin on IL-17 production of CIA mice. In the present study, we demonstrated that curcumin inhibited the production of IL-17 in vitro. The treatments of curcumin exhibited an inhibitory activity against CIA. We further demonstrated that curcumin suppressed IL-17 production of CIA mice using enzyme-linked immunospot assay and intracellular cytokine staining. We reported that curcumin had the inhibitory activity on IL-17 production in CIA mice. The suppression of CIA might result from the inhibition of IL-17 production.**

**Key words:** Curcumin, interleukin-17 (IL-17), collagen-induced arthritis (CIA)

*Accepted May 08 2011*

### **Introduction**

Previous studies have revealed that treatment with a neutralizing interleukin (IL) -17 antibody after the onset of collagen induced arthritis (CIA), which is an experimental animal model of rheumatoid arthritis (RA), significantly reduces the severity of CIA [1]. IL-17-deficient mice are resistant to the development of CIA [2]. Moreover, high level of IL-17 expression is detected in the target tissues during the progression of various human autoimmune diseases [3]. These data suggest that IL-17 plays a key role in the induction and propagation of autoimmunity [4].

Curcumin (1,7-Bis (4-hydroxy-3-methoxyphenyl)-1,6 heptadiene-3,5-di-one) is an active ingredient derived from rhizomes of *Curcuma longa* Linn., displaying remarkable antiinflammatory and antiarthritic activities. These beneficial effects have been attributed to the capacity of curcumin to prevent activation of nuclear factor-kappa B and the subsequent overexpression of proinflammatory mediators; cytokines, adhesion molecules, cyclooxygenase-2, phospholipase A<sub>2</sub>, myeloperoxidase, collagenase, as well as to its ability to modulate activities of T lymphocytes and macrophages [5-8].

Furthermore, curcumin might have the inhibitory effect on the development of CIA [9, 10]. However, it is unclear whether the inhibitory effect against CIA is related with IL-17 production. As IL-17 plays a very important role in process of the autoimmune arthritis, we wondered whether curcumin has any effects on IL-17 production in CIA mice.

In the present study, we demonstrated that curcumin directly and significantly inhibited production of IL-17 in vitro. Moreover, we examined that the effect of curcumin on an experimental animal model of RA [11], which was IL-17 mediated autoimmune disease [3].

### **Materials and Methods**

#### **Animals**

Six-week-old female DBA/1J mice were purchased from Nihon SLC, Shizuoka, Japan. All experiments were conducted in accordance with the institutional ethical guidelines for the care and use of laboratory animals of Chiba Institute of Science.

### **Collagen-induced arthritis**

Native bovine type II collagen (BCII, Chondrex, Redmond, WA, USA) was emulsified in complete Freund's adjuvant (CFA, Chondrex, USA). The mice had 100 µg BCII in CFA injected subcutaneously to the base of the tail. A booster injection containing 100 µg emulsified BCII in incomplete Freund's adjuvant (IFA, Chondrex) was given intraperitoneally on day 21 after the first immunization [11]. Arthritis scores were assigned according to Wood's assessment [12]. All paws except the injected paw were graded from 0 to 4 points. The score was defined as the sum of the scores of all paws of each mouse.

### **Curcumin treatments of CIA mice**

Curcumin (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 0.4 % methylcellulose (Shin-Etsu Chemical Industry, Co., Ltd., Tokyo, Japan), and orally administered to the mice at 100 mg/kg daily from day 21 until the end of the experiment (day 33). Mice in the control group receive equal volume of 0.4 % methylcellulose solution.

### **Preparation of splenocytes**

The mice were sacrificed by cervical spine dislocation. After they had been sacrificed, their spleens were aseptically removed and crushed into a single cell suspension, and their red blood cells were lysed with Tris-buffered ammonium chloride. The single-cell suspensions were prepared in RPMI 1640 medium containing 10 % heat-inactivated fetal calf serum (FCS, Invitrogen, Life Technologies Co., Carlsbad, CA, USA).

### **Detection of cytokine production by ELISA**

Splenocytes ( $2 \times 10^6$  cells/ml) were stimulated with phorbol myristate acetate (PMA, 0.05 µg/ml) and ionomycin (1 µg/ml) at 37 °C for 48 hours, and the concentrations of IL-17A in the supernatants were determined by ELISA (R&D Systems Inc., Minneapolis, MN, USA), according to the manufacturer's instructions.

### **RT-PCR analysis of IL-17 mRNA expression**

Single cell suspensions ( $1 \times 10^6$  cells/ml) of each group were stimulated with PMA (0.05 µg/ml) and ionomycin (1 µg/ml) for 5 hours. The total RNA of the cells was isolated by the acid guanidinium thiocyanate-phenol-chloroform extraction method using RNAiso plus (Takara Inc, Kyoto, Japan). RNA was then reverse transcribed to cDNA using reverse transcriptase (ReverTra Ace, Toyobo, Osaka, Japan) with Oligo dT primer. The real-time PCR mixture consisted of 2.5 µl of SYBR Green Buffer, 2mM

MgCl<sub>2</sub>, 1mM dNTP, 0.01U/ml AmpErase uracil N-glycosylase, 0.05U/ml AmpliTaq Gold (Applied Biosystems, part of Life Technologies Co., Carlsbad, CA, USA), forward and reverse primers (200 nM for IL-17A and glyceraldehyde-3-phosphate dehydrogenase, GAPDH), and 2 µl cDNA samples in a total volume of 25 µl. The primer sequences are shown in Table 1. The PCR reactions were performed in a MicroAmp optical 96 well reaction plate for 40 cycles (95°C for 15 seconds, 60 °C for 1 minute) in the ABI Prism 7500 Sequence Detector (Applied Biosystems). The fluorescent signals (δCt) detected during the threshold cycle were recorded by the software installed on the machine. To standardize the target gene level with respect to the variability in RNA and cDNA quality, GAPDH was amplified under the same conditions as an internal control.

### **Intracellular cytokine staining**

Splenocytes ( $2 \times 10^6$  cells/ml) were stimulated with PMA (0.05 µg/ml) and ionomycin (1 µg/ml) for 4 hours and added brefeldin A (BFA, 5µg/ml) for the last 2 hours of each culture. Cells were first stained extracellular, fixed and permeabilized, and then stained intracellularly according to previous report [13]. The following antibodies were used :spectral red (SPRD)-labeled anti-CD4, fluorescein isothiocyanate (FITC)-labeled anti-IL-17A (eBioscience, San Diego, CA, USA). Isotype antibody with matched fluorochromes was used as controls. Samples were acquired on Epics ALTRA (Beckman Coulter, Fullerton, CA, USA) and data were analyzed with EXPO32 Analysis (Beckman Coulter).

### **Cytokine ELISPOT assay**

To evaluate the number of IL-17 producing cells, an enzyme-linked immunospot (ELISPOT) assay was performed [14]. Splenocytes ( $2 \times 10^6$  cells/ml) were stimulated with PMA (0.05 µg/ml) and ionomycin (1 µg/ml) at 37 °C for 5 hours. The stimulated cells were recovered and added to a plate (MultiScreen Filter plates, Millipore Corporation, Bedford, MA, USA) that had been coated with 50 µl of 4 µg/ml monoclonal rat anti-mouse IL-17A (R&D Systems Inc., MN, USA) in carbonate buffer and incubated overnight at 4 °C . The plate was then incubated at 37 °C for 12 hours. Thereafter, the plate was washed, and biotinylated goat anti-mouse IL-17A antibody (50 µl, 300 ng/ml, R&D Systems Inc.) was added, before the plate was incubated for 2 hours at room temperature. The plates were then washed, and 50 µl of HRP-conjugated anti-biotin goat polyclonal antibody (1/5000, Vector Laboratories, Inc.) were added, and then the plates were incubated for 1 hour at room temperature. The plate was then washed and 50 µl of 3-amino-9-ethylcarbazole (AEC) substrate (Vector Laboratories,

INC., CA, USA) were added. The developed spots were then enumerated under low magnification (x40) with a microscope.

**Results**

***The effect of curcumin on the IL-17 production of splenocytes***

To examine the direct effect of curcumin on the IL-17 production of spleen cells of normal mice, splenocytes were stimulated with Concanavalin A (ConA) in the presence of various concentrations of curcumin (Fig. 1). Dose-dependent declines in IL-17 production were observed. DMSO solvent (0.01%) of curcumin did not affect cytokine production (data not shown). The inhibitory activity of curcumin could not be attributed to its cytotoxicity, because curcumin concentrations that suppressed ConA-induced IL-17 production did not affect cell viability (data not shown).

***The effect of curcumin treatment on CIA mice***


As shown in Fig. 2, the curcumin-treated mice exhibited statistically significant lower arthritis scores than the control mice. Thirteen days exposure to curcumin did not affect the growth of the mice, as determined by their body weight (data not shown).

***Cytokine production of spleen cells in CIA mice***

To determine how curcumin affect IL-17 production in CIA mice, intracellular cytokine staining and ELISPOT was used to detect IL-17 producing cells. ELISPOT assay showed that statistically significant decreases in the numbers of IL-17 producing cells were observed in the curcumin treated CIA mice (Fig. 3a). The flow-cytometric analysis also demonstrated the decreased number of IL-17 positive cells in the splenocytes of the curcumin treated CIA mice (Fig. 3b).


Furthermore, to analyze their cytokine production, the splenocytes of each group were stimulated with PMA and ionomycin for 48 hours.

The levels of IL-17 in the supernatants were quantified by ELISA (Fig. 3c). A significant difference between the non treatment CIA mice and the curcumin treated CIA mice was observed in IL-17 production ( $p < 0.01$ ). Furthermore, the collagen specific IL-17 production in the curcumin treated CIA mice also decreased significantly (data not shown).




**Figure 1.** *Effect of curcumin on the production of IL-17*

*The splenocytes were stimulated with PMA (0.05µg/ml) and ionomycin (1µg/ml) plus different concentrations of curcumin for 48 hours. The concentrations of IL-17 in the culture supernatants were measured by ELISA. Data are expressed as the mean ± S.E.M. of three independent experiments. \*\* $p < 0.01$ , \* $p < 0.05$  vs control (0 µg/ml curcumin).*



**Figure 2.** *Effect of curcumin treatment on CIA mice.*

*Curcumin was dissolved in 0.4% methylcellulose and orally administered to the CIA mice at 100 mg/kg curcumin (Δ) daily from day 21 until the end of the experiment (day 33). CIA mice in the control group (●) receive equal volume of 0.4% methylcellulose solution (day 33). Severity assessment of arthritis was performed according to Wood's assessment [12]. All paws were graded from 0 to 4 points. The score was defined as the mean of the scores of all paws of each mouse. Data are expressed as the mean ± S.E.M. of six animals. \* $p < 0.05$  (n=6).*



**Figure 3.** The effect of curcumin on IL-17 production of mice with CIA

(a) The ELISPOT assay was used to determine the number of cells secreting IL-17 in the spleens of normal mice, CIA mice, and curcumin treated CIA mice. The results represent the mean  $\pm$  S.E.M. of four experimental wells. \*\*  $p < 0.01$ , ( $n = 4$ ).

(b) PMA-stimulated splenocytes of each group were cultured for 4 hours and added brefeldin A (5  $\mu\text{g/ml}$ ) for the last 2 hours of each culture. Cells were first stained extracellular antigen (CD4), fixed and permeabilized, and then stained intracellular IL-17. Samples were acquired on EPICS ALTRA and data were analyzed with EXPO32 Analysis. Histogram plots show IL-17 expression on CD4-gated splenocytes.

(c) Splenocytes of each group were stimulated with PMA (0.05  $\mu\text{g/ml}$ ) and ionomycin (1  $\mu\text{g/ml}$ ) for 48 hours. The levels of IL-17 in the culture supernatants were measured by ELISA. Data are expressed as the mean  $\pm$  S.E.M. of three independent experiments. There was no significant difference between the three groups. \*\*  $p < 0.01$ .

(d) Splenocytes of each group were stimulated with PMA (0.05  $\mu\text{g/ml}$ ) and ionomycin (1  $\mu\text{g/ml}$ ) for 4 hours. Total RNA was isolated and reverse transcribed to cDNA. Real-time PCR was used to analyze IL-17 gene expression in the spleen cells.

## Discussion

Some studies *in vivo* and *in vitro* indicated that curcumin is a potent anti-inflammatory agent [15]. In this study, we reported mechanisms underlying anti-inflammatory actions of curcumin in CIA.

We showed the IL-17 production of spleen cells *in vitro* was significantly decreased in a dose dependent manner by the addition of curcumin (Fig. 1). Curcumin might have a suppressive activity on IL-17 production. IL-17 has been reported to aggravate the symptoms of the ex-

perimental arthritis mice [2, 16, 17]. Thus, we examined that curcumin would be able to reduce the severity of the experimental arthritis model. Treatment of mice with curcumin decreased the clinical symptoms of CIA (Fig. 2).

The results show that curcumin has the inhibitory effect on the development of CIA, and agree with the previous studies [9, 10].

To assess IL-17 producing cells in CIA mouse, ELISPOT assay (Fig. 3a) and intracellular IL-17 staining (Fig. 3b) were performed. A significant decrease of IL-17 produc-

ing cells in the curcumin-treated CIA mice was observed. This suggests that curcumin inhibits IL-17 production in CIA mice.

The detail mechanisms of RA remain unknown. After 2 decades after proposal of the Th1/Th2 paradigm[18, 19], Th17, a new subset of helper T cells has entered the field of autoimmunity[16, 20]. Recent researches showed defective Th17 differentiation do not develop CIA [2, 21].

Curcumin is also known for the specific inhibitor of nuclear factor KB (NF-KB) and subsequent anti-inflammatory activity [22, 23]. NF-B/Rel proteins are ubiquitous transcription factors that are activated in T lymphocytes and regulate the immune response and the pathogenesis of autoimmune arthritis [24].

STAT3 and NF-KB signal pathway is required for IL-17 expression [25]. The inhibitory action of NF-KB [22, 23] and STAT3 [26-28] by curcumin may be related to its reduction of IL-17 production.

In summary, we showed that curcumin directly and significantly inhibited production of IL-17 by splenocytes. Furthermore, we demonstrated for the first time that curcumin had the inhibitory effect on the development of CIA by the suppression of IL-17 production.

## Acknowledgements

The authors would like to acknowledge the financial supports rendered by the Urakami Foundation (2009).

## References

1. Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Joosten LA, et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. *Arthritis Rheum* 2004;50(2):650-9.
2. Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. *J Immunol* 2003;171(11):6173-7.
3. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. *Nat Med* 2007;13(2):139-45.
4. Lubberts E. Th17 cytokines and arthritis. *Semin Immunopathol* 2010;32(1):43-53.
5. Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. *Eur J Cancer* 2005;41(13):1955-68.
6. Funk JL, Oyarzo JN, Frye JB, Chen G, Lantz RC, Jolad SD, et al. Turmeric extracts containing curcuminoids prevent experimental rheumatoid arthritis. *J Nat Prod* 2006;69(3):351-5.
7. Jagetia GC, Aggarwal BB. "Spicing up" of the immune system by curcumin. *J Clin Immunol* 2007;27(1):19-35.
8. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. *Anticancer Res* 2003;23(1A):363-98.
9. Moon DO, Kim MO, Choi YH, Park YM, Kim GY. Curcumin attenuates inflammatory response in IL-1beta-induced human synovial fibroblasts and collagen-induced arthritis in mouse model. *Int Immunopharmacol* 2010;10(5):605-10.
10. Mun SH, Kim HS, Kim JW, Ko NY, Kim do K, Lee BY, et al. Oral administration of curcumin suppresses production of matrix metalloproteinase (MMP)-1 and MMP-3 to ameliorate collagen-induced arthritis: inhibition of the PKCdelta/JNK/c-Jun pathway. *J Pharmacol Sci* 2009;111(1):13-21.
11. Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B. Immunisation against heterologous type II collagen induces arthritis in mice. *Nature* 1980;283(5748):666-8.
12. Wood FD, Pearson CM, Tanaka A. Capacity of mycobacterial wax D and its subfractions to induce adjuvant arthritis in rats. *Int Arch Allergy Appl Immunol* 1969;35(5):456-67.
13. Pappu BP, Dong C. Measurement of interleukin-17. *Curr Protoc Immunol* 2007;Chapter 6: Unit 6 25.
14. Okamoto Y, Abe T, Niwa T, Mizuhashi S, Nishida M. Development of a dual color enzyme-linked immunospot assay for simultaneous detection of murine T helper type 1- and T helper type 2-cells. *Immunopharmacology* 1998; 39 (2): 107-116.
15. Maheshwari RK, Singh AK, Gaddipati J, Srimal RC. Multiple biological activities of curcumin: a short review. *Life Sci* 2006;78(18):2081-7.
16. Harrington LE, Mangan PR, Weaver CT. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. *Curr Opin Immunol* 2006; 18(3): 349-56.
17. Yamaguchi Y, Fujio K, Shoda H, Okamoto A, Tsuno NH, Takahashi K, et al. IL-17B and IL-17C are associated with TNF-alpha production and contribute to the exacerbation of inflammatory arthritis. *J Immunol* 2007;179(10):7128-36.
18. Street NE, Mosmann TR. Functional diversity of T lymphocytes due to secretion of different cytokine patterns. *Faseb J* 1991;5(2):171-7.
19. Mosmann TR, Coffman RL. TH1 and TH2 cells:

- different patterns of lymphokine secretion lead to different functional properties. *Annu Rev Immunol* 1989;7:145-73.
20. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4<sup>+</sup> effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. *Nat Immunol* 2005;6(11):1123-32.
  21. Lubberts E. IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? *Cytokine* 2008;41(2):84-91.
  22. Bengmark S, Mesa MD, Gil A. Plant-derived health: the effects of turmeric and curcuminoids. *Nutr Hosp* 2009;24(3):273-81.
  23. Bremner P, Heinrich M. Natural products as targeted modulators of the nuclear factor-kappaB pathway. *J Pharm Pharmacol* 2002;54(4):453-72.
  24. Seetharaman R, Mora AL, Nabozny G, Boothby M, Chen J. Essential role of T cell NF-kappa B activation in collagen-induced arthritis. *J Immunol* 1999;163(3):1577-83.
  25. Cho ML, Kang JW, Moon YM, Nam HJ, Jhun JY, Heo SB, et al. STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. *J Immunol* 2006;176(9):5652-61.
  26. Blasius R, Reuter S, Henry E, Dicato M, Diederich M. Curcumin regulates signal transducer and activator of transcription (STAT) expression in K562 cells. *Biochem Pharmacol* 2006;72(11):1547-54.
  27. Liu YC, Hsieh CW, Wu CC, Wung BS. Chalcone inhibits the activation of NF-kappaB and STAT3 in endothelial cells via endogenous electrophile. *Life Sci* 2007;80(15):1420-30.
  28. Xie L, Li XK, Funeshima-Fuji N, Kimura H, Matsumoto Y, Isaka Y, et al. Amelioration of experimental autoimmune encephalomyelitis by curcumin treatment through inhibition of IL-17 production. *Int Immunopharmacol* 2009;9(5):575-81.

#### Correspondence to:

Yoshihiro Okamoto  
 Laboratory of Immunology and Microbiology  
 Faculty of Pharmacy, Chiba Institute of Science  
 3 Shiomi-cho, Choshi, Chiba 288-0025  
 Japan

